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Abstract 
Three sequence motifs at the N-terminus of dystrophin have previously been proposed to be important for binding to actin. By analyzing a series 
of purified bacterial fusion proteins deleted for each of these sites we have demonstrated that none of the three are critical for dystrophin-actin 
interactions. Instead, our data suggest that sequences in the N-terminal 90 amino acids of dystrophin, excluding a conserved KTFT motif, contain 
the major site for interaction with actin. 
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1. Introduction 
Duchenne and Becker muscular dystrophies (DMD/ 
BMD) are progressive, lethal muscle disorders caused by 
defects in the dystrophin gene [I]. Although complete 
cDNA sequences have been determined for the human, 
mouse, and chicken dystrophins [24], little is known of 
the precise role that this protein plays in cells. Many 
mildy affected BMD patients display in-frame deletions 
of various portions of the gene, suggesting that some 
portions of dystrophin are not critical for its function [5]. 
A complete understanding of the functional domains of 
dystrophin would clarify the role this protein plays in 
cells and the mechanisms by which mutations in the gene 
lead to progressive muscle degeneration. In addition, 
identification of sequences less important for dystrophin 
activity could facilitate the design of truncated dystro- 
phin expression vectors small enough for insertion into 
viral delivery vehicles being considered for gene therapy 
of DMD [6,7]. 
Dystrophin is localized to the cytoplasmic face of the 
sarcolemma where it has been proposed to act as a struc- 
tural component of the membrane cytoskeleton [S]. Bio- 
chemical analysis indicates that dystrophin binds to an 
integral membrane complex of glycoproteins associated 
with the laminin receptor, suggesting that dystrophin 
acts as a link between the sarcoplasmic cytoskeleton and 
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the extracellular matrix [9]. The N-terminus of dystro- 
phin displays a high degree of sequence identity with the 
spectrin family of F-actin binding proteins, including 
b-spectrin, ol-actinin, filamin, and ABP120 [2]. Recent 
studies have shown that native dystrophin binds F-actin 
in vitro [IO]. It has also been shown that fusion proteins 
containing at least the N-terminal 233 amino acids of 
dystrophin bind actin in in vitro pelleting assays, and 
actin-stress fibers in situ when expressed in non-muscle 
cells [ 1 I, 121. In addition, two putative actin binding sites 
within the N-terminus have been identified by NMR 
spectroscopy experiments using synthetic dystrophin 
peptides [13,14]. To delineate further the actin binding 
domains of dystrophin, we have expressed and isolated 
various bacterial fusion proteins containing deletions of 
the N-terminal domain of dystrophin and have tested 
their ability to bind actin in vitro. Our results demon- 
strate that a fusion protein containing only the first 90 
amino acids of dystrophin retains the ability to bind 
actin in in vitro binding assays. Furthermore, within 
these 90 amino acids, the conserved amino acids KTFT 
are not critical for the observed binding activity. These 
results suggest that additional sequences not previously 
implicated in the binding of actin must be the major 
determinants of dystrophin-actin interactions. 
2. Materials and methods 
2.1. Protein expression and purification 
Actin was prepared from rabbit muscle acetone powder as described 
by Spudich and Watt [15]. A series of maltose-binding protein (MBP) 
fusion constructs were generated by PCR using Pfu polymerase (Strat- 
agene) with murine dystrophin cDNA clones as templates [16]. PCR 
reaction conditions for plasmid amplification were essentially as de- 
scribed previously [17] except that the buffer recommended by Strat- 
agene was used. Pfu polymerase was utilized due to the 12-fold higher 
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fidelity rate claimed by the manufacturer in comparison with /~lq 
polymerase. To facilitate subcloning, the 5' oligonucleotide primer was 
designed to include an EcoRI restriction site. The 3' oligonucleotide 
primers were designed with an in-frame translation stop codon and an 
XbaI restriction site. The PCR products were digested with EcoRI and 
XbaI and then cloned into EcoRI/XbaI cut pMALCRII  (New England 
Biolabs) so that the MBP was fused in-frame with the second amino 
acid of dystrophin. The DYS/190 construct was constructed from 
DYS90 using divergent primers and recombinant PCR [18] to create an 
exact deletion of amino acids 19-22. The sequences of clones DYS90 
and DYSA90 were confirmed by dideoxy sequencing. PCR primers used 
to construct he MBP~lystrophin fusion proteins are as follows: 
5 ' CGGAATTCCTTTGGTGGGAAGAAGTAG 3 ' fo rward  
5 ' GCTCTAGACTATTCAATGCTCACTTGTTGTGGC 3 ' reverse DYS246 
5 ' GCTCTAGACTATCCAGCCATGATAGTTTTC 3 ' reverse DYS130 
5 ' GCTCTAGATTAATCAACATTATTTTTCTG 3 ' reverse DYS90 
5' GAAGATGTTCAAAAGAAATGGATAAATGCAC 3 ' fo rward  A90 
5 ' GTGCATTTATCCATTTCTTTTGAACATCTTC 3 ' reverse A90 
The C-DYS-MBP fusion plasmid was constructed by subcloning the 
3' end of the murine dystrophin cDNA coding sequence [16] as an NruI 
(blunt ended)-NotI fragment into EcoRI (blunt ended)-NotI cut 
pMAlcR plasmid so that the MBP was fused in-frame to amino acids 
3364-3678 of dystrophin ([3]; Genbank accession o. M66859). This 
fragment contains the adult mouse dystrophin stop codon ([3]; G. Cox, 
J.S.C., manuscript in preparation). 
The fusion proteins were grown and purified essentially following the 
protocol of the vector supplier (New England Biolabs). DH5~F' cells 
containing dystrophin-MBP fusion vectors were induced by addition 
of IPTG to 0.3 mM and grown for 2.5 h at 37°C with continuous 
shaking. Cells were pelleted at 4,000 x g for 20 min at 4°C, resuspended 
in CL buffer (20 mM Tris-C1, pH 7.4, 200 mM NaC1, 1 mM EDTA, 
10 mM fl-mercaptoethanol), and frozen overnight at -20°C. Upon 
thawing, the protease inhibitors aprotinin, leupeptin and PMSF were 
added to a final concentration of 0.3 ,uM, 1.0/LM and 400/IM, respec- 
tively. The cells were then lysed by sonication and spun at 14,000 × g 
for 20 min at 4°C. The supernatant was diluted 1:5 with CL buffer and 
loaded onto an amylose-resin column. Bound fusion protein was eluted 
with 10 mM maltose in CL buffer and pooled protein-containing frac- 
tions were concentrated using Centricon-30 filters (Amicon). The con- 
centration of protein was determined using a protein assay kit with BSA 
as a standard (Pierce). The purity of the fusion proteins was monitored 
by SDS-PAGE. 
2.2. Actin binding 
The solid-phase immunoassays were performed essentially as de- 
scribed by Jin and Wang [19]. F-actin (100/~g/ml) or BSA (100/lg/ml) 
diluted in AB buffer (10 mM Tris-C1, pH 7.5, 100 mM KCI, 10 mM 
MgC12, 0.2 mM ATP and 0.02% sodium azide) were adsorbed to mi- 
crotiter plates by incubating 100/A/well at 4°C overnight. After three 
rinses with AB buffer, the plate was blocked with 0.15% BSA at 4°C 
overnight and subsequently washed three times with ABT buffer (AB 
buffer + 0.1% Tween-20). All subsequent steps were carried out at 
room temperature. Purified fusion proteins or purified maltose binding 
protein were serially diluted in ABT buffer and incubated (100/ll/well) 
for 2 h followed by three 10 min washes with ABT buffer. The wells 
were then incubated for 1 h (100/d/well) with anti-MBP antiserum 
(New England Biolabs) diluted h1000 in ABT + 0.015% BSA followed 
by three 10 min washes with ABT. The wells were then incubated with 
alkaline phosphatase-conjugated anti-rabbit secondary antibody di- 
luted hl000 in ABT + 0.015% BSA followed by one 10 min wash and 
two 20 min washes in ABT. After rinsing once with AB and twice with 
10 mM diethanolamine/0.5 mM MgCI2, PNPP substrate (Sigma) was 
added (100/A/well). The reaction was stopped after 30 min by addition 
of 100/11 of 100 mM EDTA and the absorbance was measured at 405 nm. 
For the centrifuge binding assays, purified DYS246, DYS90, 
C-DYS, or MBP was mixed with purified rabbit muscle F-actin and 
incubated in binding buffer (10 mM Tris-C1, pH 8.0, 100 mM KC1, 
3 mM MgCI2, 0.2 mM ATE 0.1% Triton X-100, 0.02% sodium azide) 
for 1 h at room temperature and then subjected to centrifugation i  a 
Beckman airfuge at 30 psi for 30 rain. The pellets were recovered, mixed 
with 2 × loading dye, and an aliquot was separated by SDS-PAGE on 
an 8% gel, and stained with Coomassie blue. 
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Fig. l. Amino acid sequence of the actin binding domain of dystrophin. 
The N-terminal 251 amino acids of the murine dystrophin protein. 
Underlined are the three putative sites of interaction between dystro- 
phin and actin based on experimental results with human dystrophin 
or with similarities to other actin binding proteins. ABS1 and ABS2 
were identified by Levine et al. [13,14] using NMR spectroscopy to
identify interactions between synthetic dystrophin peptides and actin. 
ABS3 is a highly conserved stretch of amino acids shown to be impor- 
tant for actin binding of ABP-120, Bcr-Abl, and a-actinin [20-23]. 
Asterisks indicate the 3' end portion of constructs used in this study. 
3. Results 
The N-terminal 251 amino acid actin binding domain 
of murine dystrophin is shown in Fig. 1. Three sites 
previously proposed to interact with actin are underlined 
and designated ABS1, ABS2, and ABS3. ABS1 (amino 
acids 18-27) and ABS2 (amino acids 131-148) are puta- 
tive sites of interaction between actin and dystrophin 
identified by NMR spectroscopy experiments with syn- 
thetic dystrophin peptides [13,14]. ABS3 (amino acids 
91 117) is highly conserved strech of amino acids shown 
to be important for the actin binding activity of ABP 120, 
Bcr-Abl, and ~-actinin [20-23]. To determine whether 
these sites are critical for actin binding to dystrophin we 
constructed a series of C-terminal deletions that sequen- 
tially removed these putative actin binding sites and 
tested their ability to bind actin in solid-phase binding 
assays. Three fusion proteins were analyzed for their 
ability to bind actin: DYS246 (amino acids 2-246) in- 
cludes all three putative binding sites; DYS130 (amino 
acids 2-130) contains ABS1 and ABS3 but is deleted for 
ABS2; and DYS90 (amino acids 2-90) which is deleted 
for ABS2 and ABS3 but contains ABS1 (Fig. 1). Fig. 2 
shows that all three fusion proteins bound actin in a 
saturable manner, whereas the control MBP exhibited 
only non-specific binding. As a second control, a fusion 
protein containing the C-terminal 315 amino acids of 
dystrophin was found to display non-specific binding 
similar to the MBP (Fig. 2C). Apparent 50% saturation 
for all three N-terminal proteins occured in the range of 
100 nM (Fig. 2A). It was also noted that at the lower 
concentrations of dystrophin, DYS130 reproducibly 
showed a slightly lower binding affinity to actin than 
DYS246 and DYS90 (Fig. 2B, and data not shown). 
The observation that DYS90 retained the ability to 
bind actin was unexpected since it lacks the highly con- 
served binding site, ABS3. To confirm this result, we 
assayed the ability of DYS246, DYS90, and C-DYS 
to bind actin in a conventional co-sedimentation assay 
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Fig. 2. Solid-phase immunoassay. (A) The fusion proteins DYS246, 
DYS130, DYS90 and maltose binding protein (MBP) (see text) were 
analyzed for their ability to bind actin (-A) or BSA (-B) as described 
in section 2. (B) Same as in A except only the linear region of the binding 
curves are shown. (C) The fusion proteins DYS246, C-DYS, and MBP 
were analyzed for their ability to bind actin. All points are the average 
of duplicate determinations. Error bars reflect the actual data points 
in cases where the difference between the duplicate points was greater 
than 0.05 absorbance units. 
(Fig. 3). Consistent with the data from the plate binding 
assay, both DYS246 and DYS90, but not C-DYS, were 
found in the pellet in the presence of actin while very little 
was found in the pellet in the absence of actin, indicating 
that both constructs are soluble and bind actin: the con- 
trol MBP alone, like C-DYS, did not bind actin in this 
assay (data not shown). In an alternate assay, we tested 
whether a synthetic peptide of the 27 amino acid ABS3 
sequence could act as a competetive inhibitor in a plate 
binding assay or in a co-sedimentation assay. This pep- 
tide did not inhibit the binding of DYS246 to actin in 
either assay (data not shown). Together these results 
indicate that neither ABS2 nor ABS3 is required for 
dytrophin binding to actin. It therefore seemed possible 
that the binding activity of DYS90 was due to the re- 
maining site, ABS 1, which has been suggested as a poten- 
tial binding site by Levine et al. [13,14]. To test this 
hypothesis, we constructed a fusion protein (DYSd90) 
containing the first 90 amino acids of dystrophin but 
deleted for 4 amino acids, KTFT, the amino acids in 
ABSl proposed to be involved in actin interactions [14], 
and tested the ability of this protein to bind actin in the 
solid-phase binding assay. Suprisingly, DYSA90 dis- 
played only a slight decrease in its ability to bind actin 
compared with the DYS90 protein (Fig. 4). This result 
indicates that an actin-binding site other than ABSl ex- 
ists within the first 90 amino acids of murine dystrophin. 
4. Discussion 
The high degree of sequence similarity between the 
N-terminal domain of dystrophin and the spectrin family 
of F-actin binding proteins suggests that this region is 
involved in binding to the actin cytoskeletal network of 
muscle cells. Recent studies have shown that both native 
dystrophin and fusion proteins containing the N-termi- 
nus of dystrophin bind actin in vitro [lo-121. Delineation 
of the regions neccessary for the dystrophin-actin inter- 
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Fig. 3. Co-sedimentation assay. Binding assays were carried out as 
described in section 2. Lanes 1 and 2, DYS246; lanes 3 and 4, DYS90; 
lanes 5 and 6, C-DYS. Lanes 1, 3, and 5 are in the presence of actin 
and lanes 2, 4, and 6 are in the absence of actin. The concentrations of 
DYS246, DYS90 and C-DYS were 9 ,uM; actin was present at 3 PM. 
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Fig. 4. Solid-phase immunoassay. (A) The fusion proteins DYS90 and 
DYSd90 were analyzed for their ability to bind actin as described in 
materials and methods. (B) Same as in A except only the linear region 
of binding curves are shown. All points are the average of duplicate 
determinations. Error bars reflect the actual data points in cases where 
the difference between the duplicate points was greater than 0.05 ab- 
sorbance units. 
action will facilitate an understanding of the function of 
dystrophin. Based on NMR spectroscopy experiments 
and sequence similarity with other actin binding pro- 
teins, it has been proposed that dystrophin might contain 
three actin binding sites: ABSl (amino acids 18-27), 
ABS2 (amino acids 131-148) and ABS3 (amino acids 
91-117) [13,14,18,21]. To explore the role of these sites 
we have constructed four N-terminal dystrophin fusion 
proteins containing successive deletions that specifically 
eliminate the proposed actin binding sites and have as- 
sayed their ability to bind actin. We have shown that a 
fusion protein containing the N-terminal 246 amino 
acids of dystrophin binds actin in a specific manner in 
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in vitro solid-phase binding assays and in actin co-sedi- 
mentation assays. In addition, we have shown that a 
synthetic 27 amino acid peptide of ABS3 sequences fails 
to inhibit this binding and, more dramatically, that a 
construct deleted for both ABS2 and ABS3 retains the 
ability to bind actin. 
These results suggest that unlike the actin binding pro- 
teins ABP-120 and Bcr-Abl, neither ABS2 nor ABS3 is 
critical for dystrophin binding to actin. Our results are 
similar to those observed for ol-actinin in which the first 
107 amino acids were shown to bind actin in the absence 
of ABS3 [23]. However, in the case of a-actinin, the 
binding between ABSl and actin appears to be weaker 
than that of ABS3 and actin, whereas for dystrophin, the 
construct containing ABSl alone (DYS90) exhibits an 
actin binding activity similar to that of the construct 
containing all three binding sites (DYS246) (Fig. 2). Fur- 
thermore, while the experiments of Levine et al. [13,14] 
have suggested that the highly conserved amino acids, 
KTFT, of ABSl in dystrophin interact with actin, we 
have shown that deleting these 4 amino acids has little 
effect on the ability of DYS90 to bind actin. This obser- 
vation is consistent with results from mutational analysis 
of this same region of a-actinin where it was shown that 
the amino acids, KTFT, were not essential for its binding 
to actin [12]. It should be noted, however, that in the 
a-actinin study, the actin binding site ABS3 was still 
present in the KTFT deletion construct, possibly ac- 
counting for its actin binding ability. Since DYS90 con- 
tains only ABSl, our results (Fig. 4) suggest that these 
4 amino acids are not the critical amino acids involved 
in the contact sites between dystrophin and actin and/or 
that the actin binding site resides somewhere else in the 
first 90 amino acids of dystrophin. 
While this manuscript was in preparation, Fabbrizio 
et al. [24] reported the results of co-sedimentation exper- 
iments designed to delineate the actin binding site of 
human dystrophin. Their results were consistent with 
ours and demonstrated that a fusion protein joining the 
MBP with amino acids l-68 of dystrophin was capable 
of binding actin. Hence, by two independent in vitro 
assays, it has been shown that neither ABS2 nor ABS3 
is critical for dystrophin binding to actin. In addition, a 
comparison of the dissociation constants of the various 
constructs used by Fabbrizio et al. [24] suggests that 
there is an inhibitory effect of the ABS3 site on the ABSl 
site. This result is also consistent with our observation 
that a construct containing just ABSl (DYS90) appeared 
to bind actin with a greater affinity than a construct 
containing ABSl and ABS3 (DYS130) (Fig. 2B). The 
fact that DYS90 displays a greater binding activity than 
DYS130 suggests that the latter may contain a region 
that inhibits binding to actin in the absence of amino 
acids 131-246. However, it is also possible that this result 
is due to subtle changes in the conformation of the fusion 
proteins. 
K. Corrado et al. IFEBS Letters 344 (1994) 255-260 259 
From the experimental data observed to date, it ap- 
pears that a previously unidentified actin binding site 
resides within the first 68 amino acids of dystrophin and 
that this binding activity does not require amino acids 
19-22, the conserved KTFT motif. Comparing the 
dystrophin actin binding results with those of other 
members of this family of proteins, it is becoming clear 
that the sites identified by sequence homology may not 
all behave similarly with respect to their actin binding 
activity. In support of this idea, it has been shown that 
ol-actinin does not inhibit the binding of purified dystro- 
phin to actin [lo]. This observation suggests that the sites 
on actin with which the two proteins interact are inde- 
pendent and presents the possibility that dystrophin and 
ol-actinin interact with actin by different mechanisms, 
perhaps requiring additional binding sites and/or other 
interacting proteins. One possible candidate for a dystro- 
phin interacting protein is the actin binding protein, 
talin, which has been shown to bind dystrophin in vitro 
[lo]. A new putative actin binding site has also been 
suggested from the recent identification of a severely 
affected DMD patient carrying a point mutation in the 
actin binding domain of dystrophin [25]. The mutated 
amino acid (Leu54-+Arg) does not reside in any of the 
conserved binding sites, which suggests that amino acid 
54 may be important for the function of dystrophin, 
possibly due to an interaction with actin. This amino 
acid is present in each of the fusion proteins that we have 
shown to bind actin in vitro. 
A variety of studies have now been reported that dem- 
onstrate binding of bacterial expressed dystrophin pro- 
tein fragments with F-actin in vitro. The primary discre- 
pancy between these studies is the apparent dissociation 
constant for the dystrophin-actin interactions. Way et 
al. proposed a & of 44 PM [l 11, Fabbrizio et al. pro- 
posed a & in the range of l-5 PM [24], while our studies 
suggest an even greater affinity in the range of 100 nM 
(Fig. 2). These discrepancies are most likely reflecting 
variations in the experimental systems employed. Our 
study and that of Fabbrizio et al. [24] used fusion pro- 
teins, which could affect the conformation of the dystro- 
phin fragment, whereas Way et al. [l l] used bacterial 
expressed dystrophin fragments not part of a fusion pro- 
tein. Fabbrizio et al. [24] and the present study both used 
MBP fusions, however, we also used a solid-phase bind- 
ing assay that may be more sensitive that the co-sedimen- 
tation assays. Hemmings et al. also used bacterial fusion 
proteins to demonstrate actin-dystrophin binding, but 
those authors did not estimate a Kd [12]. Several groups 
have studied the binding of full-length dystrophin to 
actin. Using a solid-phase assay Senter et al. [lo] detected 
a Kd for purified dystrophin in the nM range. Fabrizio 
et al. [24] and Ervasti and Campbell [26] both demon- 
strated that dystrophin-enriched membranes or the 
dystrophin-glycoprotein complex, respectively, are able 
to bind actin in co-sedimentation assays. While each of 
these studies support the idea that actin and dystrophin 
form a direct interaction, none rule out the possibility 
that other proteins facilitate this interaction. 
Elucidation of the precise sequences required for the 
actindystrophin interaction will assist in our under- 
standing of the pathogenesis of DMD and could aid in 
the development of therapeutic approaches for this dis- 
ease. While important insights into the structural basis 
for actin binding can be gained by studies of patient 
mutations, analysis of mutant and truncated dystrophins 
both in vitro and in vivo will most likely be required to 
resolve remaining ambiguities related to the mechanism 
by which dystrophin interacts with the sarcoplasmic cy- 
toskeleton. For example, multiple studies have demon- 
strated that deletion of exons 2-7, 3, and, often, 3-7, in 
a variety of patients typically results in BMD rather than 
DMD [27-291. The larger of these deletions leads to 
production of truncated dystrophin molecules missing 
amino acids 11-217, which includes ABS l-3 [2]. The 
exon 337 deletions should be mRNA frameshifting dele- 
tions, but these frequently generate low levels of dystro- 
phin molecules that arise either by exon skipping (to 
restore the reading frame) or by translational initiation 
at an AUG codon within exon 8 [28,29]. The model 
proposed by Ervasti et al. [9] for the structure of dystro- 
phin in muscle postulates a firm interaction between 
dystrophin and actin filaments for maintenance of a link 
between the cytoskeleton and the extracellular matrix. 
Beggs et al. have demonstrated that deletions that re- 
move portions of the dystrophin N-terminus generally 
lead to low levels of protein accumulation, suggesting 
that these truncated dystrophins may be unstable as a 
result of impaired interactions with the cytoskeleton [27]. 
In this regard, while Prior et al. have demonstrated that 
mutation of amino acid 54 can lead to DMD, it is not 
clear whether this mutation affected actin binding per se 
or rendered the mutant protein unstable [25]. Similarly, 
deletion of exon 3 results in BMD characterized by low 
levels of a dystrophin molecule missing amino acids 32- 
62 [27], which spans the region shared by each of our 
actin binding constructs (Fig. 1). The observed mild 
(BMD) phenotype in multiple patients with deletions 
spanning various combinations of exons encoding the 
actin binding domain suggests that dystrophin is capable 
of forming at least a weak interaction with the cytoskel- 
eton even in the absence of a strong, direct link with 
F-actin mediated by sequences at the extreme N-termi- 
nus of dystrophin. Higher resolution analysis of the 
sequences needed for linking dystrophin to the cytoskele- 
ton will be aided by studies in cell culture and in trans- 
genie mice, experiments currently in progress. Clarifica- 
tion of the structural basis for dystrophin function will 
also facilitate the rational design of truncated mini-genes 
that could be delivered to muscles by viral vectors, and 
may suggest alternate approaches for therapy of DMD/ 
BMD. 
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